Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.39 |
| ▸ | ADA | P00813 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.34 |
| ▸ | CDA | P32320 | 7/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31541828 | 0.75 | ADORA2A (0.41) | ADORA2AADAADORA3ADORA2BADORA1 | |
| SCHEMBL21418885 | 0.73 | ADORA2A (0.39) | ADORA2AADAADORA3ADORA2BADORA1 | |
| SCHEMBL15074395 | 0.73 | CDA (0.46) | CDA | |
| SCHEMBL14583693 | 0.70 | ADORA2A (0.38) | ADORA2AADAADORA3ADORA2BADORA1 | |
| SCHEMBL15187536 | 0.70 | ADORA2A (0.38) | ADORA2AADAADORA3ADORA2BADORA1 | |
| SCHEMBL18875014 | 0.70 | ADORA2A (0.38) | ADORA2AADAADORA3ADORA2BADORA1 | |
| SCHEMBL23225546 | 0.68 | ADORA2A (0.39) | ADORA2AADAADORA3ADORA2BADORA1 | |
| SCHEMBL15070549 | 0.68 | CDA (0.49) | CDA | |
| SCHEMBL19537499 | 0.68 | ADORA2A (0.39) | ADORA2AADAADORA3ADORA2BADORA1 | |
| SCHEMBL16643735 | 0.68 | CDA (0.49) | CDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | ADORA2A 174/4885ADA 13/4885ADORA3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.